R&D Expenditures And Investors Perception For An Input On Innovation Creation And Firm Growth: Empirical Evidence From Athens Stock Exchange by Tahinakis, Panayiotis & Samarinas, Michalis
The Journal of Applied Business Research – January/February 2013 Volume 29, Number 1 
© 2013 The Clute Institute http://www.cluteinstitute.com/  125 
R&D Expenditures And Investors’ 
Perception For An Input On Innovation 
Creation And Firm Growth: Empirical 
Evidence From Athens Stock Exchange

 
Panayiotis Tahinakis, University of Macedonia, Greece 
Michalis Samarinas, University of Macedonia, Greece 
 
 
ABSTRACT 
 
The question that the present study attempts to examine, concerns whether investors value the 
potential of Greek enterprises to produce innovation, in a way that it could lead them to higher 
productivity, profitability and future growth. An answer to such a question, seems to bear 
significance for a country that tries to understand the reasons for an underachieving economy, 
struggling for growth, both macro and microeconomic. If the answer is positive, this means that 
investors are affected in their decision for buying or selling a stock by the growth prospect that 
innovation, expressed with R&D spending, creates for an enterprise. R&D expenditures are used 
in this study, since they represent the enterprise’s input for the creation of innovation (Acs & 
Audretsch, 1988) and therefore, the effort for future development and firm growth. The approach 
employed, follows the same rationale as Green et al, (1996) and Stark and Thomas (1998) do. The 
R&D data that we have utilized, are collected from all the Athens Stock Exchange, (henceforth 
ASE), public firms for the period 2005-2010 that spend on R&D. The results, unlike previous 
research, depict a strong negative relation between R&D expenditures and stock price. In other 
words, investors in this Eurozone country do not consider R&D expenditures to be creators of 
innovation that will result in future growth, but they seem to be affected negatively in their 
assessment of the firm’s financial condition by R&D spending. 
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1.  INTRODUCTION 
 
he ability of an enterprise to produce knowledge
1
 and innovation of any form is theoretically 
considered to be a key element, for the development of any enterprise. It means that there is a 
potential inflow of future benefits to the firm, resulting from an innovation input, like R&D 
expenditures that could lead to growth, an increase in firm’s profitability and consequently a rise of firm’s value 
(Fama & French, 1998). The production of knowledge and innovation is not only considered a potential asset for the 
enterprise, but also the creator of positive externalities and growth for the economy as a whole, (Arrow, 1962; 
Grossman and Helpman, 1991; Howwitt, 1999; Arnold, 2000; Funke and Strulik, 2000).   
 
Of course, the issue at hand is not so much about whether corporate innovation can produce future benefits 
for a firm, but whether this is a belief shared by those that invest in it. Specifically, the question that is generated 
especially for an economy such as the Greek one that is in need of growth, both in microeconomic and 
macroeconomic level, is whether one of the most important inputs of innovation’s production, which is considered 
to be R&D expenditures, (Acs & Audretsch, 1988; Mairesse & Mohnen, 2002; Brown et al, 2009), is actually 
acknowledged as a creator of future benefits and firm prosperity, by the investing public.  
 
 
T 
The Journal of Applied Business Research – January/February 2013 Volume 29, Number 1 
126 http://www.cluteinstitute.com/  © 2013 The Clute Institute 
Keeping in mind these remarks, this study focuses on R&D expenditures, since they constitute the initial 
event in a chain of events that can potentially result to the creation of value. Namely, the R&D generated 
innovation
2, for a firm engaging in R&D spending, results in an increase on firm’s assets and more specifically on 
Intangible Assets. According to IFRS provisions
3
, a potential satisfaction of specific recognition criteria
4
, allows for 
R&D expenditures to be capitalized and treated as a firm’s asset.  
 
Specifically, there is a two-phase procedure concerning the expenditures pertaining to the creation of an 
Intangible Asset, internally. The first phase refers to the expenditures that are considered to be analogous to the 
Research activity. The accounting treatment of these research costs is for them to be expensed immediately.  
 
The second phase in the creation of an Intangible procedure is the Development phase. If the costs incurred 
during this phase, meet the above mentioned recognition criteria, then they are capitalized creating an Intangible 
with a value equal to the sum of the development expenditures, from the day of recognition
5
, up until the end of the 
fiscal year.  
 
What is even more interesting, is that investors in developed economies, treat those exact R&D 
expenditures as an item that comprises value, either they are capitalized, or not (Green et al., 1996). This specific 
reaction of investors towards these costs can help us realize the importance of R&D expenditures, for the creation of 
innovation as one of its primary inputs.  
 
For this reason the scope of this study, can be described as an empirical search of the effect that R&D 
expenses have on the investing public in Greece and consequently on Greek stock market prices. We search for 
evidence of whether Greek investors are interested and therefore value the creation of innovation, as a source of 
future benefits and growth for the enterprise and subsequently for the whole of the economy. 
 
This research perspective becomes even more interesting, if we investigate whether there is a significant 
amount of innovation input in Greece, before trying to examine its value relevance for the investors. For this reason, 
we examine some data, comparing R&D expenditures from Greek business sector, with similar data from Euro Zone 
area and European Union (27 countries) average.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
We can observe, in Figure 1
6
, that Greek business sector seems to spend only a small amount of money in 
R&D as innovation input. Greece, is not only quite below the EU and Euro zone R&D average, but also remains 
substantially distant from the Lisbon treaty target of 3%, that was supposed to be reached until 2010. Greece’s 
spending on R&D is averaging 0.17%, in contrast with 1.19% that is the EU and Euro area average. Some may 
argue that this has to do with the small size of the market and the relevantly small size of the enterprises in Greece 
that cannot spend so much in their effort to create innovation.  
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This relatively small amount of R&D spent by the Greek business sector may mean that investors in Greece 
perceive input for innovation, as expressed with R&D expenditures, with either of two different perceptions. Either 
the small magnitude of business sector R&D raises doubts for the ability of Greek firms to create innovation, and 
consequently grow and raise value, or perhaps the fact that R&D expenses are rare, is interpreted, by the investors as 
providing firms with a relative advantage. This would mean that created innovation, translates into comparative 
advantage and consequently in higher profits, value, growth and finally stock returns. Thus, it is obvious that the 
small amount of R&D expenses as a proportion of GDP raises some specific questions that constitute the core of our 
study.  
 
The structure of the remainder of the study is formulated as follows: Section 2 provides a review of 
previous research and literature on subjects related with market valuation of R&D expenses, while section 3 
elaborates on methodological issues. Section 4, presents the data and describes the sample structure, while section 5 
analyses the empirical results found. Finally, Section 6 provides the concluding remarks of our research.       
 
2.  PREVIOUS RESEARCH 
 
Many researchers dealt with the valuation of intangibles and the investments on creation of innovation 
(R&D expenses). A significant number of these studies reach the conclusion, that investors attribute value to R&D 
expenditures, since future benefits are expected. In other words, the more an entity invests in order to create and 
reproduce knowledge and innovation through R&D, the more investors anticipate gaining in the future. 
 
Prior research, deals with valuation of R&D expenditures and whether or not investors appraise the 
potential creation of intangible value. This concept is adopted by Hirschey (1982) and Hirschey & Weygandt (1985) 
in their research. In both studies, the dependent variable of the regression model is the stock price, while the 
independent comprise of the profits, R&D expenses, advertising expenses and variables like risk, (beta coefficient) 
and sector’s growth. Especially, in Hirschey & Weygandt’s  (1985) research the dependent variable is the market 
value, divided with the replacement value of tangible assets (Tobin’s indicator (q)), while in the case of independent 
variables, they utilize intense R&D and advertising expenditures, or in other words R&D and advertising expenses 
divided by total sales. Both researches seem to conclude, that R&D expenditures constitute an indicator for stock 
price. Hirschey (1985), taking this one step further, employs a slightly alternative approach, using the excess 
valuation ratio, which can be calculated as market value, minus book value, divided by total sales. Intense R&D and 
advertising expenditures, risk, enterprise’s growth, market share of a firm, are used as independent variables. Once 
more he concludes that investors seem to treat R&D expenses as worth of value. 
 
Hirschey & Spencer (1992) and Chauvin & Hirschey (1993&1994) reach the same conclusions on their 
own research. The only difference that seems to exist in the above mentioned studies is that the coefficient of R&D 
expenditures may vary according to firm’s size or activity (production or commercial). Sougiannis (1994) focuses 
on total performance of R&D expenses. Namely, he deals with those expenses as if they are investments on 
intellectual capital and attempts to understand whether or not, investors interpret them in the same way. He 
concludes that only current R&D expenses are considered creators of value by the investors and only for the present.  
 
Chan et al, (1990) using the event study methodology, researched the change in stock prices when an 
announcement of augmented R&D expenditures, occurs. The conclusions of this study depict, that these 
announcements seem to trigger the rise of stock prices, even though the enterprise might have recorded losses. 
Hence, according to the researchers, the investors seem to value and consider these expenses as of great importance, 
treating them as long-term investments that contribute to the entity’s value. 
 
In 1996, two different studies of Lev & Sougiannis and Green et al., reach similar conclusions with the 
above mentioned. On the one hand, Lev & Sougiannis conclusions depict that R&D expenditures induce higher 
performances and argue for the capitalization of these expenses. On the other hand, Green et al. suggest that R&D 
expenditures market value is treated by the investing public, as expenses for acquirement of assets and not just like 
operational expenditures. Oswald and Zarowin in 2007 also deal with a similar topic and examine the informative 
value of capitalized R&D expenditures. They provide evidence that capitalized R&D, bears informative value 
significant for the investors, while Oswald (2008), takes this one step further and in contrast to Lev & Sougiannis 
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findings, he concludes that both firms, that either capitalize R&D, or expense them, present rather equal value 
relevance. Stark & Thomas, (1998), come up with results that validate the Green et al. findings, using a similar 
approach. Chan et al (2001) and Al – Horani et al (2003), deal with the same question and they argue that entities 
which either had bad performance in the past, or were R&D intensive
7
 are underestimated, (because the R&D 
expenses appear in the income statement rather than the balance sheet), or have abnormal returns in future financial 
years, which clearly depicts the importance that R&D expenses have for the investors.  
 
Moreover, Franzen and Radhakrishnan (2009) using a residual income valuation framework, examine the 
informative value that investors attribute to R&D expenditures, for firms that present profits and losses. Consistent 
with previous studies, R&D expenditures affect stock prices for both firms that disclose profits and losses. Kallunki 
et al. (2009), investigate whether a firm can amplify the effect that R&D expenditures create in its market valuation 
by M&As, regarding technology oriented firms. Their results depict, that the R&D expenditures effect on firm’s 
market valuation is indeed amplified, but only when two technology – oriented firms proceed to M&A.  
 
Palmon & Yezegel in 2010 provide empirical evidence about the effect, that high R&D intensity can have 
to the financial analyst’s opinion and whether this is important enough to make them alter it, or revise it. The results 
of this study suggest, that analyst’s opinion for R&D intensive firms, despite the information asymmetry and 
complexity that high R&D expenditures produce, present more valuable recommendation revisions. 
 
Of course, it is of essence to mention the existence of studies that seem to contradict the above mentioned 
conclusions. Chambers et al (2002) in their research argue that high future returns that are sometimes associated 
with high R&D expenditures, might derive from the failure of uncertainty tests of R&D expenses. Kothari et al. 
(2002), present evidence about the uncertain creation of value from R&D expenditures. This research provides 
evidence, indicating that the uncertainty of the R&D expenses’ value, is by far bigger than the one accompanying 
expenses meant for other types of investments. Hence, those two different kinds of expenses should not be confused. 
 
Furthermore, some researchers argue about whether or not they should take under consideration samples 
from firms of all sectors. In this manner the value attributed to R&D costs seems to be questioned. For example, Ely 
et al. (2003) conclude that R&D expenses in biotechnology sector are not statistically significant; therefore their 
change in size does not influence investors’ decisions. In the contrary, Hand (2005) and Xu et al (2007) end up with 
the opposite conclusions. 
 
Although a great number of studies argue that R&D expenditures hold value for the investing public, there 
are some contradictory findings, indicating that the subject needs further investigation.  
 
Many of the above mentioned methodologies have been applied utilizing UK and US data samples. These 
are two countries with developed economies, which emphasize on creation of knowledge, innovation and its 
reproduction as it is expressed with R&D expenditures. In such economies it becomes evident to the investors that 
innovation is an essential factor for the firm’s development, at least according to the findings of the majority of 
previous studies. Firm’s resources spent on input for innovation (R&D expenditures), are considered money well 
spent, initiating a flow of future benefits. Hence, it seems logical for these investors, to anticipate that the value of 
an enterprise would rise as a consequence of an R&D expenses increase, treating them as investments to acquire 
assets. So the question at hand, attempts to examine economies with firms, spending fewer resources for the creation 
of innovation. Keeping this reasoning as our background we attempt to address this issue for Greece. 
 
3.  METHODOLOGY 
 
The methodological approach of this study focuses on attempting to investigate whether stock prices, 
reflecting the decisions and attribution of value by the investors, can be influenced by R&D expenditures which 
constitute inputs for corporate innovation and potential growth. Moreover this methodology can be utilized to 
clarify, whether the treatment of the investing public towards R&D expenses, is one of investments in assets that 
will lead to future benefits, or of regular operational expenses. This research is based in the same rationale with the 
approach of Stark & Thomas (1998), Green et al (1996), and Ohlson (1995), trying to test whether R&D expenses 
can constitute an explanatory variable for stock prices. 
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We must underline the fact that our study is an exploratory research. Therefore, we don’t provide 
hypotheses, since the research conducted, aims in providing potentially useful insight into a given situation such as 
the Greek economic reality.   
 
For our multivariate regression analysis, we employ share deflated variables in order to control for scale 
related effects
8
 (Barth & Clinch, 2009). The dependent variable in our analysis will be the stock price. This variable 
is crucial for our model, since it reflects the value of an entity and incorporates the informative value attributed by 
the investors. Our first equation, following Stark & Thomas’ methodological rationale, depicts the linear relation 
between the closing stock price of an entity on the last day of March for year t+1
9
 (Pt,j) and earnings per share 
(EPSt,j) for year t and firm j. 
 
jtjtjt eEPSaaP ,,10,     (1) 
 
EPS includes the dilutive influence of R&D expenses value, since during the preparation of the firm’s 
income statement and in order for the net earnings to be estimated, it is necessary to subtract R&D expenses. For 
this reason and in order to proceed, it seems reasonable to remove their influence from earnings and examine them 
as a separate variable following the methodology of Green et al (1996) and Stark & Thomas (1998). In other words, 
since R&D expenses are deductable elements of net income on the income statement, we should add them to EPS in 
order to eliminate their dilutive effect and investigate the R&D expenses effect to the stock price, independently. 
Our goal, utilizing such a distinction is to potentially improve the ability to explain stock price. So, equation (1) with 
the addition of these two new variables transforms as follows providing us equation (2): 
 
jtjtjtjtjt eRDPSRDPSEPSaaP ,,2,,10, )(           (2) 
 
The variable RDPSt,j, represents the research and development expenses for year t and firm j, expressed in a 
per share form. EPS+RDPS, constitute earnings per share plus research and development expenditures per share, for 
year t and firm j. Summarizing equation (2), results in equation (3) that is depicted as follows:   
 
jtjtjtjt eRDPSEBRDaaP ,,2,10,          (3) 
 
Where EBRDt,j represents earnings per share before R&D or in other words EPS+RDPS;  
 
Similarly to Green et al (1996), and Stark & Thomas (1998), by adding book value as an independent 
variable in equation (3), might provide an equation form with a rather increased explanatory power for our 
dependent variable. Hence, we create the following equation (equation 4): 
 
jtjtjtjtjt eBVPSRDPSEBRDaaP ,,3,2,10,           (4) 
 
Where, BVPSt,j is the book value per share for financial year t and firm j. 
 
This last equation (equation 4) represents a linear relation between stock price (market value) and earnings, 
book value and R&D. Stark (1997) provides a similar linear form of equation, but with the addition of dividends as 
an explanatory variable. Acknowledging the Clean Surplus Relation (CSR), dividends are omitted from our model
10
. 
The estimation of equations (3) and (4) and its subsequent results could provide us with noteworthy information.  
 
Firstly, the estimation educed results can provide a statistically significant a2 coefficient. Such a finding 
could be interpreted in two different ways regarding the coefficient sign. If coefficient a2 is positive and statistically 
significant, then this can be interpreted as an indication that investors in Greece attribute value to R&D 
expenditures. Such a finding would also imply that the investing public expects an inflow of future benefits to the 
firm, due to the creation of assets that incorporate firm innovation.    
 
If coefficient a2 is negative and statistically significant, then this can be acknowledged as an indication that 
the Greek investing public attributes negative value to R&D expenditures. This would mean that investors regard 
R&D expenses not as a value bearing amount, but as an operational expense that is used by the firm’s management 
for reasons other than creating innovation and subsequent benefits and growth.  
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Another finding with interpretation similar to the latter, would be the case of -a1 = a2 coefficient. Such a 
result practically means that the market does not capitalize R&D expenses.
11
 Those expenses are not treated as if 
they will bring in future benefits, but rather as expenses that have already occurred in the present financial year and 
have been accrued. In other words, they are treated as operational expenses. The estimation results can also provide 
us with statistically insignificant a2 coefficient. If this is the case, investors in Greece do not seem to attribute any 
value to R&D expenditures. Namely, they treat them neither as investments, nor as operational expenses since they 
believe that these expenses have no influence in the entity’s creation of innovation and consequent development.  
 
Furthermore, to the above mentioned research methodology, a robustness check is introduced in our 
empirical analysis, in an attempt to verify the statistically significant findings that may potentially arise from our 
multivariate regression analysis. This additional test, controls the validity of the R&D expenditures coefficient by 
constructing a dummy variable and introducing it to equation (4), in order to substitute R&D expenditures variable 
(RDPS). The dummy variable that will be created will use as a benchmark for comparison, the average (Mean) R&D 
spending. In this way the formulated variable will equal 1 in the event of exceeding, or being equal to mean R&D 
spending and 0 in case of being below R&D spending average.  
 
Therefore, equation (4) with the substitution of RDPS by the new dummy variable DRD, formulates 
Equation (5) that can be depicted as follows: 
 
jtjtjtjtjt eDRDBVPSEBRDaaP ,,4,3,10,    (5) 
 
Where DRD is a dummy variable:   
 
DRD = 1, if R&D expenditures for firm j on year t ≥ Mean R&D expenditures for year t, zero otherwise.  
 
This reasoning attempts to provide an interpretation and validation of the regression results. The utilization 
of such a variable creates two distinct groups. The companies that record R&D expenses equal or bigger than the 
average R&D spending constitute the group of firms that are considered more intensive in the production of 
Intangible assets, while the opposite applies for companies that record fewer R&D expenses than the average R&D 
spending.  
 
If the coefficient of the RDPS variable, turns out to be statistically significant, (either with a positive or a 
negative sign) then the utilization of such a dummy variable and the estimation of equation (5), will provide the 
ability to verify whether the estimated outcome, is a result formulated by the companies that consider R&D 
spending as an opportunity for future growth, or not. The following table (Table 1), provides a brief explanation of 
the potential outcomes of estimating equations (4) and (5).   
 
Table 1 – Effects of the Estimated Coefficient Signs 
Coefficient Sign 
of RDPS 
(Equation 4) 
Coefficient Sign 
of DRD 
(Equation 5) 
Effect 
(+) 
(+) 
The higher R&D spending may be, the higher the stock price may rise. However if the 
company spends below R&D average the stock price will decrease. This might provide 
evidence that the investors’ perception towards R&D can be affected negatively by 
companies spending poorly on R&D.   
(-) 
The higher R&D spending may be, the higher the stock price may reach. Even if the company 
spends below R&D average the stock price will still increase. However if the company 
spends too much (above R&D average) the stock price will decrease. This might suggest that 
the investors’ perception towards R&D can somehow be affected negatively by companies 
spending on R&D growth potential.       
(-) 
(+) 
The higher R&D spending may be, the lower the stock price may reach. However if the 
company spends above R&D average the stock price will increase. This might provide 
evidence that the investors’ perception towards R&D is positively affected by companies 
investing on R&D potential future benefits.    
(-) 
The higher R&D spending may be, the lower the stock price may reach. However if the 
company spends below R&D average, this will increase the stock price. This might provide 
evidence that the investors’ perception towards R&D is (paradoxically) positively affected by 
companies spending poorly on R&D.     
The Journal of Applied Business Research – January/February 2013 Volume 29, Number 1 
© 2013 The Clute Institute http://www.cluteinstitute.com/  131 
Moreover, the estimation of both equations (3) and (4) can provide us with validation of whether the 
addition of Book Value and R&D expenses produces incremental value for Greek public firms, consistent with 
similar findings in accounting literature. 
 
4.  DATA AND SAMPLE SELECTION 
 
The sample used for analysis in this research consists only of public firms trading in Athens Stock 
Exchange (ASE) market for the years 2005-2010. Public firms were chosen as our sample, due to the fact that, only 
listed firms are obligated of disclosing their financial statements in accordance with IFRS. Non public firms were 
excluded, due to the inexistence of market values (stock prices) and the different accounting treatment that Greek 
GAAP present regarding R&D expenses in comparison with IFRS. It must also be duly noted that IFRS have been 
adopted at 2005 and for this reason only 6 years of firm - year observations are available.  
 
Our sample consists of those public companies that during the fiscal years, 2005 to 2010 have spent for 
R&D and therefore record R&D expenditures in their financial statements. When the annual subsamples are pooled 
together, the resulting sample is 208 firm – year observations.  This initial sample is further decreased following 
Frankel & Lee (1998), since we delete firms with negative book value that are assumed to be firms with uncertain 
future prospects. Our sample selection criteria results to a panel of 200 firm - year observations that is utilized for 
our empirical analysis. EPS, Book Value and R&D expenditures were available by HELLASTAT databank, while 
adjusted Stock Price for Greek public firms came from the UOM Database. Finally, the weighted moving average 
number of stocks was hand collected from the financial statements.     
 
Furthermore, it is important to mention that the stock prices used (P), are not those of the last day of the 
fiscal year t but the price 3 months after that, namely March 31
st
 of year t+1. This reasoning is used, in order to 
include to the stock price, the influence of financial statements’ announcement, which public companies have to 
prepare and present until the end of the third month after the end of the financial year.   
 
Book Value (BVPS) is measured as the sum of shareholder’s equity, plus reserves for year t and it is share-
deflated for scaled effects. R&D expenditures (RDPS), are recognized as items recorded in the income statement for 
year t and deflated using weighted moving average number of shares at the same year. Earnings per share for year t, 
extracted by the Statement of firm’s Financial Position, plus R&D expenditures at the same year represent EBRD 
which depict the value of Earnings before R&D expenditures.      
 
Taking under consideration the above mentioned analysis, the following table is presented, depicting the 
descriptive statistics on selected variables of our sample. 
 
Table 2 - Summary Statistics 
Variable Mean Median Std. Dev. Minimum Maximum 
PRICE 2.78109 1.50092 3.33067 0.07 21.6 
BVPS 2.48912 1.77917 2.41087 0.004041 13.587 
RDPS 0.0381 0.023294 0.04195 5.67E-06 0.2248 
EBRD 0.11718 0.107803 0.35353 -1.76753 1.22061 
Notes: The sample consists of 200 firm year observations of stock price, book value per share, R&D per share, earnings per share 
before R&D for the years 2005 to 2010. PRICE represents the stock market price taken from Athens Stock Exchange on March 31st, of 
each year. BVPS is firm's book value divided by the weighted moving average number of the firm's stocks. RDPS represents R&D 
expenditures as recorded on the income statement divided by the weighted moving average number of the firm's stocks. EBRD variable 
constitutes earnings before R&D expenditures and it has been formed by adding EPS for each firm with R&D expenditures divided by 
the weighted moving average number of firm's stocks.      
 
This table displays graphically the characteristics of the variables used, namely PRICE, BVPS, EBRD and 
RDPS. It is evident, that some relatively extreme high and low values appear in our sample. Despite utilizing some 
sample selection criteria in order to limit the occurrence of extreme values, the existence of a small sample prevents 
us from further abridging it.  
 
Furthermore it can be suggested from table 2, that R&D expenses present significantly minor amounts 
while at the same time the difference between minimum and maximum values together with the mean and median 
The Journal of Applied Business Research – January/February 2013 Volume 29, Number 1 
132 http://www.cluteinstitute.com/  © 2013 The Clute Institute 
are skewed with a concentration of frequency distributions at the lower end. The same remarks can be made for 
PRICE and BVPS variables that present a similar frequency depiction, while the contrast comes from EBRD that 
presents skewness close to zero.          
 
5.  REGRESSION RESULTS  
 
In order to extract empirical results for the case examined, a Pooled Ordinary Least Squares (OLS) 
regression has been implemented for the estimation of equations (3), (4) and (5). It has to be noted, that alternative 
estimation methods are applicable with our data sample. Both robust and maximum likelihood estimation techniques 
are applicable, but their requirements for symmetrical and normally distributed errors respectively, cannot be met in 
our case.  
 
Our choice of estimation method was also consistent with the results of the panel diagnostic tests that were 
implemented and appear to confirm our choice in the matter of heterogeneity. More specifically, we have employed 
a Hausman test for all three equations, resulting in favor of Fixed Effects estimation in all cases
12
. Our next panel 
diagnostic test was the implementation of an F-test for joint significance of Fixed Effects, resulting to the adequacy 
of Pooled OLS regression estimation
13
 for the three equations
14
 over Fixed Effects estimation.  
 
The regression analysis that has been employed was OLS, following White’s approach (1980) for 
heteroscedasticity consistent standard errors and covariance. The outcomes of the estimated regressions can be seen 
in the following table (Table 3).   
 
Table 3 - Pooled OLS estimates for Equations 3, 4 and 5 
  const EBRD RDPS BVPS DRD Adj. R
2
 Akaike 
Equation 3 2.4145*** 5.8999*** -8.6657**   0.3271 972.59 
 (10.17) (4.525) (-2.183)     
Equation 4 2.02978*** 5.56676*** -8.77918** 0.174121*  0.3383 970.21 
 (6.45) (4.111) (-2.125) (1.691)    
Equation 5 1.97017*** 5.54966***  0.17044** -0.74439* 0.3373 970.51 
  (6.44) (9.018)  (2.038) (-1.774)   
Equation 3: jtjtjtjt eRDPSEBRDaaP ,,2,10,    
Equation 4: jtjtjtjtjt eBVPSRDPSEBRDaaP ,,3,2,10,    
Equation 5: jtjtjtjtjt eDRDBVPSEBRDaaP ,,4,3,10,    
Notes: All models use PRICE as a dependent variable. PRICE represents the closing stock market price taken from Athens Stock 
Exchange on March 31st, of the year t+1. BVPS is firm's book value for year t divided by the weighted moving average number of the 
firm's stocks. RDPS represents R&D expenditures for year t as recorded on the income statement divided by the weighted moving 
average number of the firm's stocks. EBRD variable constitutes earnings before R&D expenditures and it has been formulated by adding 
each firm's EPS for year t with each firm's R&D expenditures for year t divided by the weighted moving average number of firm's stocks. 
DRD is a dummy variable that equals 1 if R&D expenditures for firm j on year t ≥ Mean R&D expenditures for year t and zero 
otherwise.    
For all three equations the methodology of heteroscedasticity-consistent standard errors and covariance is utilized. Pooled OLS was 
employed with our data after rejecting the incorporation of Fixed or Random Effects. This was decided after conducting for both models 
an F-Test for joint significance of Fixed Effects and Hausman test. 
***, ** and * represent a 1%, 5% and 10% statistical significance in the respective cases while the values in the parentheses depict the 
t-statistic value. 
 
It is obvious from the OLS estimation results of equation (3), that the coefficients of variables EBRD and 
RDPS, as well as the intercept are statistically significant. The level of significance is estimated at 1%, for 
coefficients of the intercept and EBRD, while RDPS bears a statistical significance of 5%. The finding whose 
peculiarity seems to attract the attention in this estimation and differs from previous research findings, is the 
negative sign of RDPS coefficient. Its value is equal to a quite substantial -8.66, demonstrating a negative relation 
between stock prices and R&D expenditures. The Adjusted R² of the equation’s (3) estimation is 0.32, presenting a 
reasonable degree of explanatory power, while the Akaike criteria is valued at 972.59.  
 
The pooled OLS estimation for equation (4), presents similar findings with the previous equation. As 
depicted in Table 3 the coefficients of all variables, namely, EBRD, RDPS, BVPS, as well as the intercept appear to 
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be statistically significant. The coefficients for the equation’s intercept and EBRD variable, maintain the 1% level of 
significance, but with a vast drop of a rather noticeable 40% in the statistical significance of the intercept. The 
correlated omitted variable bias that occurs in Ohlson’s model in the case of the intercept, that is being statistically 
significant, seems to apply here. The absence of an important variable from Equation (3) that is later incorporated in 
Equation (4), namely BVPS, seems to be responsible for this drop in the value of the t - statistic.  
 
The table also suggests that RDPS and BVPS have a 5% and 10% level of significance, respectively. The 
Adjusted R² of the equation’s (4) estimation is 0.33, demonstrating an improvement with the addition of BVPS on 
this estimation. Table 3, also provides us with a smaller figure of the Akaike criteria which is now equal to 970.21, 
presenting an improvement in comparison with equation (3) with the addition of BVPS variable. This finding 
suggests that the incorporation of BVPS variable, adds on the incremental value of the stock price, a result 
consistent with previous literature.  
 
The finding that once more attracts the attention regarding RDPS variable, is the existence of a result 
analogous with what we observed in equation (3). A substantial figure equal to -8.77 is estimated, depicting once 
more a negative relation with the dependent variable. The value of the RDPS coefficient has not changed despite the 
introduction of a new variable to our equation.  
 
The negative sign of the statistically significant estimation, regarding RDPS, is not consistent with previous 
findings, since it suggests an inverse relation between the innovation input, namely R&D expenses and stock price.  
 
The estimation result of equation (4) regarding RDPS is validated by utilizing a robustness check that 
further analyses our model by estimating, with OLS regression analysis, equation (5). The estimates of this equation, 
present a statistical significance of 1% for both EBRD variable and the intercept, without a significant change on the 
coefficient values or signs. BVPS, is also statistically significant for 5%, while Adjusted R
2
 and Akaike criterion are 
about the same with the estimation of Equation (4) resulting in 33% and 970.51 respectively.  
 
The estimate of the DRD dummy variable seems to verify the results of equation (4) estimation. The 
coefficient amounts at a statistically significant -0.74, depicting once more a negative relation between R&D 
spending and stock prices. This negative coefficient implies that the higher (above average) the R&D spending may 
be for a firm, the bigger the negative effect may be on its stock price and vice versa, thus depicting a paradox that is 
not consistent with the previous literature and the growth potential that R&D as an innovation creator might imply.  
 
Investing public in Greece does not seem to value R&D expenditures as a value creator for both the firm 
and the economy and seem to believe that future benefits cannot flow towards the firm that invests in innovation. As 
a matter of fact, estimation of equation (5) incorporates a new perspective, suggesting that if a company spends 
below R&D spending average, this will result in an increase of the stock price, implying that investors’ perception 
towards R&D is positively affected by companies spending poorly on R&D.        
 
6.  CONCLUSIONS  
 
This paper attempts to examine whether investors value the potential of Greek enterprises to produce 
innovation. The question at hand can be else wise summarized in whether investors are affected in their decision for 
buying or selling a stock, by the growth prospect that innovation, expressed with R&D spending, creates for an 
enterprise.  
 
R&D expenditures are the main focus of this empirical study, since they represent the enterprise’s input for 
the creation of innovation and therefore the effort for future development and firm growth.  
 
Our empirical analysis, using a Eurozone country in economic turmoil, depicts the corporate rationale 
behind the creation of innovation through R&D spending. The outcomes of our estimation depict that Research and 
Development expenditures, play the role of anything but the innovation creator, at least in the minds of the investors.  
 
Our findings are consistent with previous literature in terms of utilizing a methodology like the one that 
Stark & Thomas (1998) do, and the incorporation of BV as an improvement of the initial model. Our results are also 
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consistent with previous literature, in terms that the investing public attributes value in R&D expenditures. The 
difference that draws attention in Greek economic reality, as mentioned earlier, is that investors attribute a negative 
value in public firms’ R&D spending. Not only do they not consider that R&D expenditures can produce innovation 
that will result in future growth, but they also seem to be affected negatively in their assessment of the firm’s 
financial condition. The less a company seems to spend for R&D the better it may be.     
 
Perhaps, even this small amount of business sector created intangibles in Greece, cannot be perceived as a 
competitive advantage, making firms investing on them, distinguishable in the minds of the investing public. 
Perhaps, either the small magnitude of business sector R&D, raises doubts for the ability of Greek firms to create 
innovation and consequently grow and raise value, or the innovation created constitutes innovation via adoption, a 
fact that if true, raises an important question for the general growth and well being of the Greek private sector and 
subsequently for the Greek economy as a whole.  
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ENDNOTES 
 
1
 An earlier version of this paper has been presented at the 3
rd
 International Conference on Accounting and Finance 
in Skiathos, Greece, 26
th
-27
th
 of August 2010.   
2
 We refer to the knowledge that can potentially be capitalized and constitute an intangible asset. For example a 
computer software that incorporates knowledge for a specific production procedure. 
3
 e.g. patents, copyrights, trademarks 
4
 IAS 38, §10, §21, §57 
5
 IAS 38 provisions determine the general recognition criteria for the creation of identifiable Intangible Assets. §10 
and §21 provide the following criteria that need to be satisfied:  
a) The created Intangible Asset must be identified separately from other aspects of the business entity. 
b) The use of the created Intangible Asset must be controlled by the entity that creates it as a result of its 
past actions and events. 
c) There must be future economic benefits expected to flow to the entity from the creation of the 
Intangible Asset. 
d) The cost of the created Intangible asset must be measured in a reliable way.     
Moreover IAS 38, §57 refers specifically on the additional recognition criteria that needs to be satisfied in order to 
capitalize the Development expenses. So the entity must demonstrate all the following: 
a) Technical feasibility of completing the intangible asset. 
b) Intention to complete the Intangible asset and either use it or sell it. 
c) The ability to use or sell the created asset. 
d) The capacity of the created intangible asset to generate future economic benefits. 
e) The entity’s ability to measure in a reliable manner the costs incurred for the creation of the Intangible 
Asset.   
6
 Of course it needs to be stated that once costs have been expensed during the development phase they can no 
longer be capitalized.  
7
 The data have been extracted from the Eurostat database. The years 2008 and 2009 for Greece are projections 
made by the International Statistical Yearbook. 
8
  01,0
esexpenditur&
intensity& 
Sales
DR
DR  
9
 We utilize weighted moving average number of stocks for the variables utilized.  
10
 This reasoning is used, in order to include to the stock price, the influence of financial statements’ 
announcement. 
11
 A similar approach is followed by Stark and Thomas (1998)  
12
 In this case equation (3) becomes as follows with –a1 = a2 : 
   
tttttttttt BVRDRDaEPSaaPBVRDRDEPSaaP 321103210 )(  
 
   
ttttt BVRDRDaEPSaaP 32220  
 RD are eliminated, so: 
   
ttt BVEPSaaP 320   
13
Hausman test statistic Equation (3): 
H = 10.3537, p-value =  0.005645 in favor of the fixed effects model. 
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Hausman test statistic Equation (4): 
H = 14.5258, p-value =  0.00227015 in favor of the fixed effects model. 
Hausman test statistic Equation (5): 
H = 14.2981, p-value =  0.00252617 in favor of the fixed effects model. 
14
F-Test: equation (3) 
F(44, 153) = 1,05632 with p-value 0,39295 accepting the null hypothesis that Pooled OLS is adequate 
F-Test: equation (4) 
F(44, 152) = 1,10622 with p-value 0,321296 accepting the null hypothesis that Pooled OLS is adequate 
F-Test: equation (5) 
F(44, 152) = 1,1414 with p-value 0,275655 accepting the null hypothesis that Pooled OLS is adequate   
15
A Breusch-Pagan test was not performed since the Hausman test had already rejected the implementation of 
Random Effects Estimation. 
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